INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.

doi:10.1186/s12885-020-07008-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.

BMC cancer - 5 Jun 2020

van Tilburg Cornelis M, Witt Ruth, Heiss Melanie, Pajtler Kristian W, Plass Christoph, Poschke Isabel, Platten Michael, Harting Inga, Sedlaczek Oliver, Freitag Angelika, Meyrath David, Taylor Lenka, Balasubramanian Gnana Prakash, Jäger Natalie, Pfaff Elke, Jones Barbara C, Milde Till, Pfister Stefan M, Jones David T W, Kopp-Schneider Annette, Witt Olaf

Abstract excerpt

BACKGROUND: Pediatric patients with relapsed or refractory disease represent a population with a desperate medical need. The aim of the INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) program is to translate next generation molecular diagnostics into a biomarker driven treatment strategy. The program consists of two major foundations: the INFORM registry providing a molecular screening...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bayes Theorem

Share to Benzamides

Share to Drug Monitoring

Share to Drug Resistance, Neoplasm

Share to Nivolumab

Share to Precision Medicine

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 32503469
DOI: 10.1186/s12885-020-07008-8
PMCID: PMC7275428

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.PMID 32503469Read ↗

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.Semantic proximity Read ↗

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.Semantic proximity Read ↗

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trialSemantic proximity Read ↗

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumorsSemantic proximity Read ↗

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaSemantic proximity Read ↗

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trialSemantic proximity Read ↗

Functional Precision Medicine Enhances Clinical Outcomes of Relapsed/Refractory Pediatric and Adolescent Cancer PatientsSemantic proximity Read ↗

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.